A manifest of our clinical trials

REMAP-CAP

Primary Outcome: Day 90 mortality for pneumonia patients >>

MEGAROX

Trial Update: The Mega-ROX trial has now hit 25,000 enrolments worldwide with only 15,000 more to go >>

PLATIPUS

Trial Update: The Mega-ROX trial has now hit 25,000 enrolments worldwide with only 15,000 more to go >>

  • REMAP-CAP

    Trial news: REMAP-CAP has been announced as one of three finalists for the Federartie Medisch Specialisten Science and Innovation Prize 2023.

  • MEGAROX

    Trial Update: The Mega-ROX trial has now hit 25,000 enrolments worldwide with only 15,000 more to go

  • PLATIPUS

    PLATIPUS uses an adaptive platform design, running multiple “domains” concurrently

• Improving outcomes for babies born preterm

• Improving outcomes for babies born preterm

Primary outcome:
Improving outcomes for babies born preterm

PLATIPUS uses an adaptive platform design, running multiple “domains” concurrently

REMAP-CAP

Primary Outcome: Day 90 mortality for pneumonia patients

Trial news: REMAP-CAP has been announced as one of three finalists for the Federartie Medisch Specialisten Science and Innovation Prize 2023. More on this here.